The weekly buprenorphine injection gives people in treatment for opioid use disorder a way to receive medication that works consistently across all seven days, without a daily pill or film to manage. Understanding how it works, why the injectable form behaves differently in the body, and what to expect at each appointment helps you go into treatment with realistic expectations and a clear sense of what you’re signing up for.
What a Weekly Buprenorphine Injection Is
A weekly buprenorphine injection is a subcutaneous, extended-release formulation of buprenorphine, sold under the brand name Brixadi, that is injected once every seven days by a licensed clinician in a healthcare setting. It is not a film you dissolve under your tongue, not a tablet, and not something you take home. The entire dose is delivered at the appointment, and it releases steadily into your system over the following week.
Brixadi is FDA-approved specifically for the treatment of opioid use disorder (OUD) in adults. That distinction matters: this is a regulated medical treatment, not a workaround or a substitute addiction. The Centers for Disease Control and Prevention estimates that more than 2.7 million Americans have an opioid use disorder, and fewer than 25 percent receive any form of medication-assisted treatment. In Maryland, the opioid crisis has driven some of the highest overdose mortality rates in the country, with the Maryland Department of Health reporting more than 2,400 overdose deaths in 2023. The gap between people who need treatment and people who receive effective medication is the problem this form of treatment exists to close.
Brixadi is available to patients on Medicaid, commercial insurance plans, and self-pay. Insurance coverage is addressed in more detail later in this article, but access is not limited to people with private plans.
How Buprenorphine Works in the Brain
Buprenorphine is a partial opioid agonist. That phrase is worth unpacking in plain English because it explains almost everything about why this medication works.
Opioid receptors in the brain, specifically mu-opioid receptors, are the binding sites that opioids like heroin, fentanyl, and oxycodone attach to. When a full agonist like heroin binds to those receptors, it activates them completely, producing intense euphoria, sedation, and, at high enough doses, respiratory depression. Buprenorphine binds to the same receptors, but it is a partial agonist: it activates them, but not fully. More importantly, it binds with extremely high affinity, meaning it latches on tightly and stays there.
A 2016 review published in CNS Drugs, analyzing receptor occupancy data across multiple pharmacokinetic studies, found that buprenorphine achieves 80 to 95 percent mu-opioid receptor occupancy at therapeutic doses. What this means in practice: when those receptors are occupied by buprenorphine, there is physically no room for heroin or fentanyl to bind. The blocking effect is not a matter of willpower or motivation. It is receptor pharmacology.
The Ceiling Effect: Why It’s Safer Than Methadone or Full Agonists
One of buprenorphine’s most clinically significant properties is what pharmacologists call the ceiling effect. Above a certain dose threshold, additional buprenorphine does not produce additional respiratory depression. The dose-response curve flattens. This is fundamentally different from methadone, which is a full agonist with a linear dose-response relationship, meaning more methadone continues to suppress breathing in direct proportion to the dose.
The FDA’s prescribing information for Brixadi explicitly identifies the ceiling effect as a reason the drug carries a lower risk of fatal overdose from the medication itself compared to full agonists. For patients managing co-occurring mental health conditions who take antidepressants, antipsychotics, or other medications, this ceiling effect creates a meaningful safety margin. The combination of buprenorphine with other CNS depressants still requires caution (covered in the side effects section), but the ceiling effect means the medication itself is significantly less likely to cause respiratory failure than methadone or street opioids.
Why Cravings Decrease on Buprenorphine
Sustained receptor occupancy is the mechanism behind craving reduction. When mu-opioid receptors are consistently occupied, the brain’s opioid-driven craving signal loses its biochemical grip. The brain stops sending the urgent, compulsive drive to use because the receptors it would normally be signaling through are already engaged.
A 2019 clinical study published in Drug and Alcohol Dependence, following 287 patients across 16 weeks of buprenorphine treatment, found statistically significant reductions in opioid craving scores beginning in week one, with further reductions through week four. The practical takeaway from this data: if cravings diminish in the first week of treatment, that is the medication working, not a sign that you were never really dependent. Reframing that experience matters because many patients mistake early craving relief for evidence they no longer need medication. The biology says otherwise.
What Makes the Injectable Form Different From Sublingual Buprenorphine
Sublingual buprenorphine, whether as films (Suboxone, Subutex) or tablets, has been the standard delivery method for decades. It works. But the delivery method creates specific limitations that the injectable form eliminates.
When you dissolve a film under your tongue, absorption is variable. Saliva volume, how long you hold it, whether you ate recently, even the pH of your mouth all affect how much buprenorphine actually enters your bloodstream. A 2017 pharmacokinetic review in the Journal of Clinical Pharmacology found that sublingual bioavailability of buprenorphine ranges from 30 to 55 percent across patients, with significant intra-individual variability on different days. The injectable subcutaneous formulation delivers a precisely measured dose directly into subcutaneous tissue, where it absorbs at a controlled rate. Bioavailability is more consistent and more predictable.
For patients who have struggled with remembering to take daily doses, managing medication around work schedules, or navigating situations where taking a daily film feels conspicuous or difficult, the once-weekly injection removes all of that. One appointment. Seven days of consistent coverage. No daily decision to manage.
Steady Blood Levels vs. Daily Peaks and Troughs
Sublingual dosing creates a predictable pharmacokinetic pattern: plasma levels peak within a few hours of taking the medication, then drop toward a trough in the hours before the next dose. For many patients, those trough windows are when cravings or mild withdrawal symptoms return. It is not a dramatic effect for everyone, but it is real enough that some patients describe feeling “off” in the evenings or early mornings before their next dose.
The injectable extended-release formulation does not produce those peaks and troughs. A 2023 pharmacokinetic study published in Clinical Pharmacokinetics, analyzing plasma concentration data from the Brixadi phase 3 program, confirmed that subcutaneous buprenorphine maintains stable plasma levels throughout the seven-day dosing interval with minimal fluctuation. In practical terms, day three feels the same as day seven. There is no window in the week where the medication’s effect fades enough to let cravings back in.
No Diversion Risk, No Daily Dose Management
Diversion of sublingual buprenorphine films is a documented public health concern. SAMHSA data from 2022 estimates that a meaningful portion of buprenorphine misuse involves diverted take-home strips, and for patients living in households where other family members struggle with substance use, having controlled medication in the home creates real stress and real risk.
Because the weekly injection is administered in a clinical setting and never leaves with you, diversion is structurally impossible. There is nothing to share, sell, or accidentally leave accessible. For patients in households with active substance use, this is not a minor convenience. It removes an entire category of worry from the treatment experience. If you are [looking for a provider in Maryland](/ brixadi-provider-maryland) who offers this format, the in-office administration model is a consistent feature across clinics offering Brixadi.
The Injection Itself: What Happens at the Appointment
Most patients expect the appointment to take significantly longer than it does. In practice, a weekly injection appointment typically runs 15 to 30 minutes, including the clinical check-in.
Before the injection, a clinician conducts a brief assessment. For new patients at induction, this includes a withdrawal assessment using the Clinical Opiate Withdrawal Scale (COWS) to confirm readiness. For established patients returning for a subsequent dose, the check-in is shorter: a brief review of how the week went, any side effects, craving levels, and any changes in medications or health status.
The injection itself is subcutaneous, meaning it goes into the fatty tissue just beneath the skin rather than into a muscle or vein. The abdomen and upper arm are the standard sites. The clinician rotates sites across appointments to minimize irritation. The injection takes under a minute. Some patients describe mild stinging during administration; others describe it as barely noticeable.
The Brixadi phase 3 trials, published in JAMA Network Open in 2022 and involving 428 patients across multiple sites, reported high rates of patient satisfaction with the injection procedure itself, with the majority of participants rating the administration experience as acceptable or better after their first appointment.
Who Administers It and Where
The weekly buprenorphine injection cannot be self-administered or taken home. It must be delivered by a licensed clinician in a healthcare setting, consistent with DEA and SAMHSA regulations governing buprenorphine administration. In practice, this means a prescriber or trained clinical staff member at a licensed treatment facility performs each injection at each appointment.
Maryland clinics offering this service include locations in Baltimore, College Park, Linthicum Heights, Nottingham, and Owings Mills. For your first injection appointment, bring a government-issued photo ID, your insurance card (or documentation of Medicaid coverage), and a list of any current medications, including over-the-counter supplements. If you have prior treatment records from another provider, those are useful but not required to begin.
What to Expect at the Injection Site
After the injection, it is normal to notice mild swelling, redness, or a small firm nodule at the site. These local reactions are the most commonly reported side effect in clinical trials, occurring in approximately 30 to 40 percent of patients according to the Brixadi prescribing information, and the majority resolve within a few days without intervention.
Warmth and tenderness at the site in the first 24 to 48 hours are expected. Rotating injection sites at each appointment reduces cumulative irritation. Signs that warrant a call to the clinic are infection indicators: increasing redness spreading beyond the injection site, pus, fever, or pain that worsens rather than improves after 48 hours. For most patients, none of those occur. Missing the next dose because of a site reaction is rarely necessary.
Starting the Weekly Injection: Eligibility and Induction
Adults with moderate to severe opioid use disorder are candidates for the weekly buprenorphine injection, including people dependent on heroin, illicit fentanyl, or prescription opioids like oxycodone or hydrocodone. There is no requirement to have tried other treatment options first.
The induction process is where the main clinical requirement lives. Because buprenorphine has high receptor affinity and displaces other opioids from mu-receptors, starting the medication when opioids are still heavily present in the system can trigger precipitated withdrawal, a sudden, severe withdrawal syndrome caused by buprenorphine displacing the opioids and partially activating receptors that were fully activated before. Precipitated withdrawal is not dangerous in a medical sense, but it is intensely uncomfortable and it discourages patients from continuing treatment.
To avoid precipitated withdrawal, the FDA induction protocol for buprenorphine requires patients to be in at least mild-to-moderate spontaneous withdrawal before the first dose, confirmed by a COWS score. The 2022 JAMA Network Open phase 3 trial data for Brixadi used a COWS threshold of 8 or greater for induction eligibility, which corresponds to the early stages of withdrawal. This means feeling some discomfort before the first appointment is not a sign something has gone wrong. It is a clinical prerequisite.
Transitioning From Sublingual Buprenorphine
Patients already stable on sublingual buprenorphine films or tablets have the most straightforward path to the weekly injection. Because the medication is the same, transitioning does not require a restart of induction. The first injection dose is calculated based on the current sublingual dose using established equivalency data from the Brixadi prescribing information.
Before your first injection, you take your last sublingual dose as usual and then skip the next scheduled sublingual dose. The injection appointment is scheduled for when mild withdrawal would naturally begin. If you are currently on sublingual buprenorphine and want to switch, the direct conversation to have with your current prescriber is: “I want to transition to the extended-release weekly injection formulation.” From there, the dose calculation and timing are clinical decisions the prescriber manages. You can also find details on starting this process at Maryland locations that offer coordinated transitions.
Starting Fresh: Induction From Active Opioid Use
For patients coming directly from active heroin or fentanyl use, induction timing is more complex, specifically because of fentanyl’s pharmacokinetic profile. Fentanyl accumulates in fatty tissue and releases back into the bloodstream slowly, meaning withdrawal onset is often delayed compared to heroin. A 2021 study in Drug and Alcohol Dependence examining fentanyl-era induction outcomes found that patients with primary fentanyl use disorder experienced withdrawal onset 24 to 72 hours after last use, compared to 8 to 24 hours for heroin.
The practical implication: do not use opioids after midnight the night before your induction appointment, and aim for at least 24 hours of abstinence if your primary drug is fentanyl. Feeling uncomfortable and symptomatic at the appointment is the goal. Arriving high or having used within the last few hours is the scenario to avoid. The clinical team will score your withdrawal level before proceeding, and if the timing is not right, they will work with you on rescheduling rather than forcing an induction that risks precipitated withdrawal.
Dosing: Weekly vs. Monthly Options
Brixadi is available in both weekly and monthly formulations, and this is one of the things that distinguishes it from other extended-release buprenorphine options. The weekly format gives prescribers the ability to assess your response at seven-day intervals during the early weeks of treatment, adjust the dose based on how you are responding, and then transition to monthly dosing once your dose is stabilized and your treatment is going well.
Starting on weekly dosing does not mean staying on it permanently. For many patients, the weekly phase is a calibration period, typically lasting four to eight weeks, before moving to monthly injections. The clinical rationale, supported by the Brixadi prescribing data, is that weekly dosing early in treatment allows for more frequent dose adjustments when the need for titration is highest. Once stable, monthly dosing reduces the number of required clinic visits without sacrificing coverage. You can read more about what a structured Brixadi treatment program looks like and how the dosing timeline fits into a broader care plan.
How Dose Adjustments Work
Buprenorphine dosing is not uniform across patients. Factors including body weight, prior opioid tolerance, and individual pharmacokinetics all influence how a given dose feels and performs. The FDA-approved dose range for Brixadi weekly injections spans from 8 mg to 32 mg per week. Prescribers start at a dose calibrated to the patient’s prior sublingual dose or estimated opioid tolerance and adjust based on clinical response at subsequent appointments.
If the first weekly dose feels insufficient, meaning cravings persist, withdrawal symptoms return before the seven-day mark, or you feel a compulsive urge to use, tell your provider directly at the next appointment. The same applies to side effects like nausea or headache. Dose adjustments are a routine part of early treatment, not a sign that the medication is not working for you.
Effectiveness: What the Research Shows
The clearest evidence for injectable buprenorphine comes from the RECOVER trial, a phase 3 randomized controlled trial published in JAMA Network Open in 2022. The study enrolled 428 adults with moderate to severe opioid use disorder across 36 U.S. sites and compared weekly subcutaneous buprenorphine against placebo. The primary outcome was the percentage of urine drug screens negative for illicit opioids across the 24-week treatment period. Patients receiving the weekly injection had 41.3 percent of their urine screens negative for illicit opioids, compared to 5.0 percent in the placebo group. That is not a marginal difference. It is a foundational demonstration that consistent medication coverage substantially changes behavior.
In plain language: sustained, steady medication delivery meaningfully reduces illicit opioid use. The comparison to placebo also underscores the core argument for medication-assisted treatment overall: behavioral willpower alone, without pharmacological support, produces a fraction of the outcomes.
Retention in Treatment
Retention in treatment is one of the strongest predictors of long-term recovery outcomes in opioid use disorder research. Every month a patient stays in treatment is a month their biology has time to restabilize, their support systems have time to rebuild, and their risk of fatal overdose is dramatically reduced. A 2020 study in JAMA Psychiatry, analyzing outcomes data from 40,000 patients across commercial and Medicaid claims, found that patients who stayed in buprenorphine treatment for 12 months or longer had a 65 percent lower rate of opioid-related emergency department visits compared to those who discontinued within 90 days.
Extended-release injectable formulations consistently demonstrate stronger retention than sublingual formulations in head-to-head studies. The mechanism is not mysterious: removing the daily dosing decision removes the daily opportunity to discontinue. A patient who does not have to remember a pill or film at 7 a.m. is not confronted daily with the micro-decision of whether to take it. The injection already happened. The coverage is already in place.
Reduction in Illicit Opioid Use
The RECOVER trial’s 41.3 percent negative urine screen rate is not the ceiling for outcomes. In real-world clinical settings, patients who combine medication with counseling and continued engagement in care show higher rates of sustained abstinence. But even standing alone, the medication’s impact on urine screen outcomes is measurable from the first weeks of treatment.
What you should realistically expect on urine drug screens in the first month: some patients show clean screens within the first week, particularly if they enter treatment from a period of attempted abstinence. Others show continued positivity for opioids in weeks one and two as fentanyl metabolites clear from tissue stores. A positive screen in week two is not evidence the medication is not working. It can reflect the pharmacokinetics of fentanyl clearance rather than ongoing use. Your provider interprets those results in clinical context, not as pass-fail grading.
Impact on Overdose Risk
A 2020 analysis published in Annals of Internal Medicine, using data from 17,568 Medicaid patients in North Carolina, found that patients actively engaged in buprenorphine treatment had a 65 percent reduction in overdose mortality compared to periods when they were not in treatment. The mechanism behind that reduction for injectable buprenorphine specifically involves sustained receptor occupancy: when receptors are partially occupied by buprenorphine around the clock, a relapse episode involving heroin or fentanyl is less likely to be immediately fatal because the full agonist cannot bind as completely.
If a relapse occurs while on the weekly injection, the most important action is to contact the clinic immediately and not use alone. The injection’s receptor occupancy does not eliminate overdose risk, especially with high-potency fentanyl analogs in the current supply. Carrying naloxone and telling someone you trust how to use it remains a sound practice regardless of where you are in treatment.
Side Effects and How to Manage Them
The most commonly reported side effects with Brixadi, drawn from the prescribing information and the phase 3 clinical trial data, are injection-site reactions (discussed above), headache, nausea, constipation, and insomnia. These are not unique to the injectable formulation: they are common across buprenorphine delivery methods and reflect both the pharmacology of the medication and the body adjusting to reduced opioid receptor stimulation after a period of heavier use.
For most patients, these side effects are most pronounced in the first one to two weeks of treatment and diminish as the body adapts. Nausea responds well to taking the injection with a light meal or snack at the appointment. Constipation benefits from increased water intake and fiber. Insomnia in the first week often reflects the broader withdrawal resolution process rather than a direct medication effect. If side effects persist beyond the first two weeks or feel unmanageable, adjusting the dose at the next appointment is the appropriate clinical response.
Serious adverse events are uncommon but warrant immediate attention: signs of a severe allergic reaction (rash spreading across the body, difficulty breathing, swelling of the face or throat), sudden severe abdominal pain, or significant confusion or sedation outside the context of other CNS depressant use should prompt a call to the clinic or emergency services.
Serious Warnings: Drug Interactions and CNS Depressants
The FDA issued a black box warning in 2016 on the combination of opioid medications, including buprenorphine, with benzodiazepines, alcohol, and other central nervous system depressants. The warning is explicit: the combination can cause slow or difficulty breathing, sedation, coma, and death. The risk does not disappear because buprenorphine is a partial agonist. When combined with benzodiazepines like alprazolam or diazepam, or with alcohol, the additive CNS depression can be clinically significant.
This does not mean that patients who have a benzodiazepine prescription for anxiety or PTSD cannot receive buprenorphine treatment. It means that full disclosure to your prescriber is non-negotiable before the first injection. List every medication you take, including benzodiazepines prescribed by another provider, sleep aids, antihistamines with sedating properties, and alcohol use. Your prescriber needs that information to manage the combination safely, which may include coordinating with your other prescribers or adjusting doses. Withholding this information does not reduce your risk. It increases it.
Insurance Coverage and Cost in Maryland
Cost is a legitimate concern for this audience, and the answer is more reassuring than most patients expect. Maryland Medicaid covers Brixadi as an FDA-approved medication for opioid use disorder, consistent with federal Medicaid requirements that mandate coverage for all FDA-approved medication-assisted treatment medications. If you are enrolled in Maryland Medicaid, your injection and the associated clinical visits should be covered with minimal or no out-of-pocket cost, though specific plan details can vary.
Commercial insurance plans, including employer-sponsored plans and marketplace plans, are required under the Mental Health Parity and Addiction Equity Act to cover substance use disorder treatment comparably to medical treatment. In practice, this means most commercial plans cover Brixadi, though prior authorization requirements vary by insurer. A 2023 SAMHSA analysis of insurance claims data found that prior authorization approval rates for buprenorphine medications exceeded 85 percent for commercial plans when submitted with appropriate clinical documentation.
For patients without insurance, the manufacturer of Brixadi operates a patient assistance program. Before your first appointment, ask the intake coordinator directly: what will my out-of-pocket cost be, and does the clinic handle prior authorization? Clinics experienced in administering Brixadi typically manage the insurance coordination process as part of intake, which means you do not have to navigate it alone. For guidance on what to look for when selecting a provider in Maryland, insurance coordination capacity is one of the most practical questions to ask upfront.
Combining the Injection With Counseling and Mental Health Support
Medication is the clinical foundation of treatment for opioid use disorder, and it is also not the complete picture. Depression, anxiety, PTSD, and trauma histories are common among people seeking treatment for OUD, and those conditions do not resolve because opioid cravings are suppressed. SAMHSA’s 2023 Treatment Improvement Protocol (TIP 63) on medications for opioid use disorder recommends integrated care, meaning behavioral health services delivered alongside medication, as the standard of care for most patients.
A 2019 study in JAMA Psychiatry, following 1,269 patients with opioid use disorder across 30 treatment sites, found that patients receiving medication plus integrated behavioral health services had 28 percent higher treatment retention at six months compared to those receiving medication alone. The mechanism is not complicated: medication stabilizes the neurobiology while counseling addresses the patterns, relationships, and mental health conditions that intersect with substance use. One does not replace the other.
In practice, integrated care at a clinic offering both medication administration and behavioral health means your prescriber and your counselor are working from the same clinical picture. Your mental health history informs how your OUD treatment is structured, and your OUD treatment informs how your mental health care is delivered. If you are evaluating what a full treatment program involves beyond the injection itself, the presence or absence of co-located behavioral health services is one of the most meaningful features to assess.
How Buprenorphine Changes What Recovery Looks Like
Understanding the weekly buprenorphine injection well enough to make an informed decision about it requires holding two ideas at once: the medication is highly effective, and it is also not a passive experience. The research is unambiguous that sustained medication coverage reduces illicit opioid use, prevents overdose deaths, and keeps people in treatment long enough for meaningful life change to occur. None of that happens automatically or without engagement.
What changes once you understand the mechanism is the way you interpret your own experience in treatment. Cravings dropping in week one are not luck. Stable mood across a seven-day dosing interval is not coincidence. A negative urine screen in week three is not proof you no longer need medication. All of it is the pharmacology working as designed, and knowing that reframes every milestone from a personal moral achievement to a clinical signal that the treatment is doing its job.
The most common misconception worth leaving behind: that needing medication long-term is a sign of treatment failure. The research on opioid use disorder, including a landmark 2014 analysis in JAMA Psychiatry following patients for five years post-treatment, consistently shows that longer duration of buprenorphine treatment produces better long-term outcomes. There is no evidence-based timeline that requires stopping medication at any specific point. Duration is a clinical decision made between you and your provider based on your response, your circumstances, and your goals.
If you are ready to move from understanding the medication to scheduling an appointment, contact a Maryland clinic offering the weekly buprenorphine injection and ask specifically for a consultation about Brixadi. Name your insurance coverage at intake so the team can confirm prior authorization before your first appointment. Locations in Baltimore, College Park, Linthicum Heights, Nottingham, and Owings Mills offer in-office injection services with scheduling and insurance coordination handled as part of the intake process.